Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)

2024-511246-39-00 Protocol 1479-0001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 27 Jul 2021 · Status Ongoing, recruiting · 8 EU/EEA countries · 26 sites · Protocol 1479-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 592
Countries 8
Sites 26

Solid tumours with HER2 aberrations

Key facts

Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Jul 2021 → ongoing
Decision date (initial)
2024-09-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511246-39-00
EudraCT number
2020-004563-47
WHO UTN
U1111-1312-5969

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid tumours with HER2 aberrations

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Boehringer Ingelheim Espana S.A.

Sponsor organisation
Boehringer Ingelheim Espana S.A.
Address
Carrer Prat De La Riba 50, Sant Cugat Del Valles Sant Cugat Del Valles
City
Barcelona
Postcode
08174
Country
Spain

Locations

8 EU/EEA countries · 26 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 2 1
France Ongoing, recruiting 31 6
Germany Ongoing, recruiting 20 5
Italy Ongoing, recruiting 2 3
Netherlands Ongoing, recruiting 71 2
Portugal Ongoing, recruiting 1 2
Spain Ongoing, recruiting 33 6
Sweden Ongoing, recruiting 2 1
Rest of world
Korea, Republic of, Australia, United States, United Kingdom, Japan, Israel, China, Singapore, Hong Kong
430

Investigational sites

Belgium

1 site · Ongoing, recruiting
Institut Jules Bordet
Oncology department, Mijlenmeersstraat 90, 1070, Anderlecht

France

6 sites · Ongoing, recruiting
Institut Curie
Oncologie Médicale, 26 Rue D Ulm, 75005, Paris
Centre Hospitalier Regional De Marseille
Unité de Phase I Oncologie labélisée CLIP, 264 Rue Saint Pierre, 13005, Marseille
Institut Gustave Roussy
Service d’Onco-Pneumologie, 39 Rue Camille Desmoulins, 94805, Villejuif Cedex
Centre Leon Berard
Oncologie Médicale, 28 Rue Laennec, 69008, Lyon
Hospices Civils De Lyon
Plateforme de traitements oncologiques, 59 Boulevard Pinel, 69500, Bron
Centre Hospitalier Universitaire De Rennes
Unité d'Investigation Clinique, 2 Rue Henri Le Guilloux, 35000, Rennes

Germany

5 sites · Ongoing, recruiting
Universitaetsklinikum Augsburg
II. Medizinische Klinik, Stenglinstrasse 2, Kriegshaber, Augsburg
Pius-Hospital Oldenburg
Klinik für Hämatologie und Onkologie, Georgstrasse 12, Innenstadt, Oldenburg
Justus-Liebig-Universitaet Giessen
Universitätsklinikum Gießen und Marburg GmbH, Gaffkystrasse 5, 35392, Giessen
University Hospital Cologne AöR
Klinik I für Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne
Technische Universitaet Dresden
Medizinische Klinik und Poliklinik I, Fetscherstrasse 74, Johannstadt-Nord, Dresden

Italy

3 sites · Ongoing, recruiting
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Oncologia Medica, Strada Provinciale 142 Orba Km 3,95, 10060, Candiolo
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Sc Ematologia Oncologia, Via Mariano Semmola 52, 80131, Naples
Azienda Ospedaliero Universitaria Parma
U. O. di Oncologia Medica, Viale Antonio Gramsci 14, 43126, Parma

Netherlands

2 sites · Ongoing, recruiting
Leids Universitair Medisch Centrum (LUMC)
Longziekten, Albinusdreef 2, 2333 ZA, Leiden
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Klinische Farmacologie, Plesmanlaan 121, 1066 CX, Amsterdam

Portugal

2 sites · Ongoing, recruiting
Hospital Cuf Descobertas S.A.
Serviço de Oncologia, Rua Mario Botas 1, 1998-018, Lisbon
Hospital CUF Porto S.A.
Serviço Pneumologia, Estrada Da Circunvalacao N 14341, 4100-180, Porto

Spain

6 sites · Ongoing, recruiting
Hospital General Universitario Gregorio Maranon
Thoracic Oncology, Head & Neck and Sarcoma Unit, Calle Del Doctor Esquerdo 46, 28007, Madrid
Hospital Clinico Universitario De Valencia
Servicio de Hematología y Oncología, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Virgen De La Victoria
UGC Oncología Intercentros, Calle Del Arroyo Teatinos S/N, 29010, Malaga
Hospital Universitario 12 De Octubre
Servicio de Oncología, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitari Vall D Hebron
Servicio de Oncología Médica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Institut Catala D'oncologia
Department of Medical Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat

Sweden

1 site · Ongoing, recruiting
Karolinska University Hospital
Studie behandlingsavdelning, B08:09, Eugeniavagen 3, 171 64, Solna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2023-09-27 2024-01-22
France 2023-06-19 2023-06-21
Germany 2023-04-20 2023-06-13
Italy 2023-10-19 2023-12-01
Netherlands 2021-07-27 2021-08-20
Portugal 2023-09-25 2024-05-16
Spain 2023-05-05 2023-05-30
Sweden 2023-09-28 2023-10-19

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-03 Spain Acceptable with conditions
2024-09-25
2024-09-25
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-04 Spain Acceptable
2025-03-31
2025-03-31
3 SUBSTANTIAL MODIFICATION SM-2 2025-05-02 Spain Acceptable
2025-08-08
2025-08-08
4 SUBSTANTIAL MODIFICATION SM-4 2025-09-02 Acceptable 2025-09-18
5 SUBSTANTIAL MODIFICATION SM-5 2025-09-02 Spain Acceptable 2025-10-20
6 SUBSTANTIAL MODIFICATION SM-6 2025-09-02 Acceptable 2025-10-08
7 SUBSTANTIAL MODIFICATION SM-3 2025-09-03 Acceptable 2025-10-08
8 SUBSTANTIAL MODIFICATION SM-7 2025-11-19 Spain Acceptable
2026-01-29
2026-01-29
9 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-20 Spain Acceptable
2026-01-29
2026-05-20